Weight-Based Torsemide Dosing in Subjects With Heart Failure
Heart Failure
About this trial
This is an interventional treatment trial for Heart Failure focused on measuring Torsemide, loop diuretics, weight-based
Eligibility Criteria
Inclusion Criteria:
- All subjects with admission diagnosis of heart failure, including heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) treated with loop diuretics during hospitalization
- Must be at least 18 years old at time of enrollment
- Must have reliable access to a telephone, and be able to speak and understand English or Spanish over a telephone connection
Exclusion Criteria:
- Any subject who is currently pregnant
- Any subject with end-stage renal disease requiring hemodialysis
- Any subject with serum potassium concentration < 3.5 mEq/L at discharge
- Any subject with serum magnesium concentration < 1.4 mg/dL at discharge
- Any subject with a known history of allergic reaction to loop diuretics
- Any subject with known severe stenotic valvular heart disease
- Any subject who requires chronic inotropic pharmacotherapy
- Any subject undergoing evaluation for cardiac transplantation or left-ventricular assist device
- Any subject who is not able to provide informed consent
Sites / Locations
- Jacobi Medical Cent
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Weight-Based Torsemide Group
Standard Outpatient Management Group
Subjects will be randomized to complete a weight-based torsemide dosing regimen for their outpatient heart failure management. These subjects will prescribed a specified dose of torsemide on discharge from the hospital and subsequently have a phone encounter with a physician three times a week where their dose of torsemide will be titrated based on an algorithm which factors in current symptoms and weight. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
Subjects will be randomized to standard outpatient heart failure management where they will be prescribed a fixed daily dose of a loop diuretic upon discharge from the hospital and have a follow-up appointment within one week of discharge. All medications including loop diuretic type, dose and frequency will be managed at the discretion of the patient's primary care physician or cardiologist. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.